Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPA and Antioxidants in Schizophrenia
NCT00419146Phase 3Completed
- Sponsor
- Aker Hospital
- Start
- Sep 2001
- Primary completion
- Apr 2004
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of Epadel, vitamin e, ascorbic acid in schizophrenia, schizoaffective disorder, schizophreniform disorder, sponsored by Aker Hospital. Started Sep 2001; status: completed.
02
Drugs
Epadelvitamin eascorbic acid
03
Conditions
schizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on NCT00419146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00419146.